MEG3, MEG8, and MALAT1 upregulation, and PVT1 downregulation were involved in GDM development and the adverse effects on offspring, which provides novel biomarkers or therapeutic targets for GDM [6, 7, 9, 45]. This evidence concerns the gene MALAT1 and gestational diabetes.